New Recommended MAb Pairs
D-dimer has been commonly elevated in patients with SARS-CoV-2. It has been shown to correlate with disease severity and to be a reliable prognostic marker for hospitalization and mortality assessment in patients admitted for COVID-19. Elevated levels of D-dimer have been found in the blood of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT). The elevated level of D-dimer in blood is believed to be a reliable marker of pathological coagulation.
For the accurate determination of D-dimer, assays must not detect fibrinogen and its degradation products (D-monomer). To this end, Advanced ImmunoChemical offers D-dimer produced from clotted fibrinogen by means of plasmin digestion. And we also supply D-dimer MAb pairs.
D-dimer (MW 180 kDa) is the final product of fibrin degradation. It consists of the remnants of all three chains (α, β and γ chains) of fibrinogen cross linked by disulfide bonds. The dimeric structure of D-dimer is held by two covalent, intermolecular isopeptide bonds between the γ-chains.
For development of D-dimer assays, we offer several monoclonal antibodies specific for D-dimer and FDP. The recommended capture-detection pairs for sandwich immunoassays are shown below:
DD189cc – DD255cc: Equal specificity for D-dimer and high mw fibrin degradation products.
DD2 – DD41cc: Slightly more specific for high mw fibrin degradation products.
DD2 – DD4: Approximately equal specificity for D-dimer and high mw fibrin degradation products.
Note: due to the cross-reactivity of MAb DD4 with fibrinogen, it is strongly recommended to use it as the detection antibody. In a sandwich immunoassay, plasma must be diluted at least 2-fold with 10 mM Tris-HCl, pH 7.5, 1 M NaCl, and 0.1% Tween-20 in order to avoid non-specific binding. Each step in the assay should be followed by an incubation step and washing; coating with the capture MAb, addition of the sample, and addition of the (conjugated) detection MAb.
See product details, AssayNotes, and ordering information: